熊猫体育-官网网址

Shanghai, China, August 28, 2024 – Genor Biopharma (Stock code: 6998.HK) today announced its interim results for 2024, sharing the company's business progress, financial data, highlights during the period, and future development prospects.

Shanghai, China, August 5, 2024 - Genor Biopharma (Stock code: 6998.HK) announced today that the company had entered into a licensing agreement and a stock purchase agreement with TRC 2004.Under the License Agreement, Genor Biopharma has agreed, among others, to grant the Licensee an exclusive worldwide license to develop, use, manufacture, commercialize and otherwise exploit GB261 (CD20/CD3, BsAb) , excluding mainland China, Hong Kong, Macau and Taiwan.

Shanghai, China, March 28, 2024 – Genor Biopharma (Stock code: 6998.HK) announced today its 2023 annual financial results, business progress and other highlights in the past year.

China National Medical Products Administration (NMPA) has officially accepted the new drug application for GB491 (Lerociclib, cyclin-dependent kinase 4/6 inhibitor) combined with Letrozole for the treatment of HR-positive, HER2-negative patients with advanced breast cancer who have not previously undergone systemic antitumor therapy.

Genor Biopharma participated at the 65th American Society of Hematology (ASH) Annual Meeting held in San Diego, USA on December 9-12, 2023, and shared the poster of the preliminary clinical safety and efficacy results of the phase I/II study of GB261(CD20/CD3).